
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
IRBM, announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, continuing their long-standing history of collaboration that began in 2010. This new agreement is focused on advancing peptide therapeutics.
Read the full release






